Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.59 |
| ▸ | QPCT | Q16769 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL4769098 | 0.88 | QPCT (0.48) | PRKCIQPCTMAPTKDM4ERAD52 | |
| Piperidine SCHEMBL4724630 | 0.86 | QPCT (0.47) | PRKCIQPCTMAPTKDM4ERAD52 | |
| Methylethylamine SCHEMBL4767397 | 0.86 | QPCT (0.50) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL28178020 | 0.84 | PSMD11 (0.64) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL31150505 | 0.83 | PARP1 (0.49) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL903276 | 0.83 | PARP1 (0.52) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL23636201 | 0.80 | MMP12 (0.60) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL30467970 | 0.80 | MMP12 (0.60) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL29804939 | 0.80 | QPCT (0.60) | PRKCIQPCTMAPTKDM4ERAD52 | |
| SCHEMBL23227938 | 0.80 | QPCT (0.60) | PRKCIQPCTMAPTKDM4ERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107955020-B | Method for synthesizing benzimidazol oxazinone compound by copper salt catalysis in one pot | 西南大学 | 2020-09-22 | — | — | CN | claimed |
| EP-3340982-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | claimed |
| CN-107955020-A | The method of mantoquita catalysis one-pot synthesis benzimidazole and oxazine ketone compounds | 西南大学 | 2018-04-24 | — | — | CN | claimed |
| CN-105646366-B | The synthetic method of benzimidazole nitrence base class compound | 西南大学 | 2018-03-30 | — | — | CN | claimed |
| WO-2017035408-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | claimed |
| CN-105435744-A | Method for preparing zeolite-like imidazate framework material for adsorbing n-alkanes in naphtha | UNIV CHANGZHOU | 2016-03-30 | — | — | CN | claimed |
| US-12544382-B2 | 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-02-10 | — | — | US | disclosed |
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-12234398-B2 | Metal organic framework (MOF) glass composite comprising metal halide perovskite | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-02-25 | — | — | US | disclosed |
| US-20240376377-A1 | A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-11-14 | — | — | US | disclosed |
| CN-118829643-A | Metal Organic Framework (MOF) glass composites comprising metal halide perovskite | 昆士兰大学 | 2024-10-22 | — | — | CN | disclosed |
| CN-118619944-A | 2,4, 6-Trisubstituted pyrimidine compounds as ATR kinase inhibitors | 北京泰德制药股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4397156-A1 | A METAL ORGANIC FRAMEWORK (MOF) GLASS COMPOSITE COMPRISING METAL HALIDE PEROVSKITE | The University of Queensland (AU) | 2024-07-10 | — | — | EP | disclosed |
| WO-2004069829-A1 | (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004014899-A1 | THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| US-5380643-A | Cyanine dye sensitizer, rhodium salt, no fogging in storage, contrast | KONICA CORPORATION (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0589649-A1 | A silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5153116-A | Using a isothiazol-3-one or 1,2-benzoisothiazol-3-one compound in a layer also containing a spectral sensitizing dye; monochromatic films; negatives | KONICA CORPORATION (JP) | 1992-10-06 | — | — | US | disclosed |
| EP-0367243-A1 | A silver halide photographic light-sensitive material excellent in antistatic property | KONICA CORPORATION (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-3935314-A | Anti-hypertensive compositions of benzimidazole derivatives | BEECHAM GROUP LIMITED (EN) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338230-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | PRKCI 2426/4885QPCT 2716/4885MAPT 4523/4885 |
| US-12544382-B2 | 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor | ATR, CHEK1, CHEK2 | PRKCI 252/4885QPCT 3582/4885MAPT 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.